Davis's Drug Guide
everolimus
General
High Alert Medication: This medication bears a heightened risk of causing significant patient harm when it is used in error.
Genetic Implications:
Pronunciation:
e-ver-oh-li-mus
To hear audio pronunciation of this topic, purchase a subscription or log in.Trade Name(s)
- Afinitor
- Afinitor Disperz
- Zortress
Ther. Class.
Pharm. Class.
kinase inhibitors
There's more to see -- the rest of this topic is available only to subscribers.
Citation
Vallerand, April Hazard., et al. "Everolimus." Davis's Drug Guide, 19th ed., F.A. Davis Company, 2024. Pediatrics Central, peds.unboundmedicine.com/pedscentral/view/Davis-Drug-Guide/109389/all/everolimus.
Vallerand AHA, Sanoski CAC, Quiring CC. Everolimus. Davis's Drug Guide. F.A. Davis Company; 2024. https://peds.unboundmedicine.com/pedscentral/view/Davis-Drug-Guide/109389/all/everolimus. Accessed November 17, 2024.
Vallerand, A. H., Sanoski, C. A., & Quiring, C. (2024). Everolimus. In Davis's Drug Guide (19th ed.). F.A. Davis Company. https://peds.unboundmedicine.com/pedscentral/view/Davis-Drug-Guide/109389/all/everolimus
Vallerand AHA, Sanoski CAC, Quiring CC. Everolimus [Internet]. In: Davis's Drug Guide. F.A. Davis Company; 2024. [cited 2024 November 17]. Available from: https://peds.unboundmedicine.com/pedscentral/view/Davis-Drug-Guide/109389/all/everolimus.
* Article titles in AMA citation format should be in sentence-case
TY - ELEC
T1 - everolimus
ID - 109389
A1 - Sanoski,Cynthia A,
AU - Vallerand,April Hazard,
AU - Quiring,Courtney,
BT - Davis's Drug Guide
UR - https://peds.unboundmedicine.com/pedscentral/view/Davis-Drug-Guide/109389/all/everolimus
PB - F.A. Davis Company
ET - 19
DB - Pediatrics Central
DP - Unbound Medicine
ER -
